News
-
-
PRESS RELEASE
NeuroSync Laboratories Publishes Peer-Reviewed Scientific Research Paper Demonstrating Anti-Nausea Effect of C-Infinity
NeuroSync Labs' groundbreaking research on mitigating motion sickness in virtual reality (VR) published in Neuroscience Letters highlights the use of C-Infinity controller for immersive and nausea-free VR experiences -
PRESS RELEASE
NeuroSync Laboratories Unveils Revolutionary VR Gaming Experience With C-Infinity
NeuroSync Labs announced the launch of its groundbreaking product C-Infinity on Kickstarter. This 21st-century neuro-digital interface revolutionizes VR gaming, offering an immersive and nausea-free experience. The C-Infinity, resembling an upright standing VR simulator, provides true locomotion and a direct brain-to-machine interface, setting new standards for virtual interaction. Backers can now avail a limited-time discount of over 60% on Kickstarter on January 23. For more information about NeuroSync Labs or C-Infinity, please visit https://neurosyncvr.com.
-
Buildout, Inc. Unveils Game-Changing Technology Stack including an AI-Enabled Mobile App
-
Heal and Find Hope After a Friendship Breakup in When Best Friends Aren't Forever by Kristen Reed, Out Now
-
Viking Capital Announces Closing of Latest 268 Acquisition in Atlanta
-
Aflac: 6 Common Myths About Supplemental Insurance
-
Gabriel Resources Ltd. Initial Closing of Private Placement
-
Original-Research: Noctiluca S.A. (von East Value Research GmbH ):
-
Eurobattery Minerals increases its stake in the Finnish Hautalampi project to 100 per cent
-
Cairn Homes Plc: Transaction in Own Shares
-
Dalata Hotel Group PLC: HOL-Holding(s) in Company*
-
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
-
VOGO : French National Handball League chooses VOGO to referee the French men’s championship (“Liqui Moly Starligue”).
-
ENGIE Q1 2024 Financial Information
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2024